A Randomised, Blinded, Placebo-controlled, Single Centre Pilot Study to evaluate the Safety and Efficacy of AVX001 3% Ointment (NG) administered Topically Once Daily to Patients with mild, moderate or severe Atopic Dermatitis.
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs AVX 001 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Avexxin
- 22 Mar 2017 Status changed from recruiting to completed.
- 03 Nov 2016 New trial record